PMC8047622_01
Case 1 (A) PET computed tomography (CT) at diagnosis reveals hypermetabolic activities of right hilar, mediastinal (white arrow) and supra-clavicular lymph nodes (black arrow). (B) PET CT three years after diagnosis shows complete metabolic response.
fonc-11-644282-g001.jpg
PMC8047622_01_fonc-11-644282-g001.jpg
f1
A 58-year-old woman presented in November 2016 with a diagnosis of KRAS-mutant advanced lung adenocarcinoma ( Figure 1A ). Tumor response remained complete more than 3 years after chemotherapy discontinuation and no further episode of digital ischemia occurred ( Figure 1B ).
PMC8047622_02
Case 2 (A-C) PET CT at diagnosis shows an intensely hypermetabolic mass at right lower lobe adjacent to mediastinum (white arrows). (D, E) CT image of the chest performed 16 months after diagnosis shows partial response of the primary lung tumor (white arrows).
fonc-11-644282-g002.jpg
PMC8047622_02_fonc-11-644282-g002.jpg
f2
PD-L1 negative metastatic lung squamous cell carcinoma was subsequently made ( Figures 2A-C ) and gemcitabine-platinum combination was started. Partial objective tumor response was observed after four cycles and maintenance gemcitabine was pursued. Despite this event, patient had no sign of cancer recurrence and duration of tumor objective response achieved 16 months ( Figures 2D, E  ).